Disease Domain | Count |
---|---|
Neoplasms | 3 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Monoclonal antibody | 1 |
miRNA | 1 |
Recombinant polypeptide | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date18 Sep 2024 |
Sponsor / Collaborator |
Start Date03 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
miR-195 | Carotid Stenosis More | Preclinical |
Indoxyl sulfate | Chronic Kidney Diseases More | Preclinical |
US20220409704 ( PREX2 ) | Neoplasms More | Discovery |
WO2022228380 ( CXCR2 ) | Neoplasms More | Discovery |
Capsinolol ( β1-adrenergic receptor ) | Arrhythmias, Cardiac More | Pending |